These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
449 related articles for article (PubMed ID: 24595805)
61. Preoperative treatment with capecitabine, bevacizumab and radiotherapy for primary locally advanced rectal cancer--a two stage phase II clinical trial. Resch G; De Vries A; Öfner D; Eisterer W; Rabl H; Jagoditsch M; Gnant M; Thaler J; Radiother Oncol; 2012 Jan; 102(1):10-3. PubMed ID: 21741716 [TBL] [Abstract][Full Text] [Related]
62. Technical feasibility of laparoscopic total mesorectal excision for patients with low rectal cancer after concurrent radiation and chemotherapy with bevacizumab plus FOLFOX. Liang JT; Lai HS; Cheng KW Surg Endosc; 2011 Jan; 25(1):305-8. PubMed ID: 20526625 [TBL] [Abstract][Full Text] [Related]
63. T3+ and T4 rectal cancer patients seem to benefit from the addition of oxaliplatin to the neoadjuvant chemoradiation regimen. Martijnse IS; Dudink RL; Kusters M; Vermeer TA; West NP; Nieuwenhuijzen GA; van Lijnschoten I; Martijn H; Creemers GJ; Lemmens VE; van de Velde CJ; Sebag-Montefiore D; Glynne-Jones R; Quirke P; Rutten HJ Ann Surg Oncol; 2012 Feb; 19(2):392-401. PubMed ID: 21792506 [TBL] [Abstract][Full Text] [Related]
64. Neoadjuvant therapy of bevacizumab in combination with oxaliplatin and capecitabine (XELOX) for patients with metastatic colorectal cancer with unresectable liver metastases: a phase II, open-label, single-arm, noncomparative trial. Chen HH; Lin JK; Chen JB; Chuang CH; Liu MC; Wang JY; Changchien CR Asia Pac J Clin Oncol; 2018 Feb; 14(1):61-68. PubMed ID: 28906589 [TBL] [Abstract][Full Text] [Related]
65. Predictive factors of tumor response after neoadjuvant chemoradiation for locally advanced rectal cancer. Moureau-Zabotto L; Farnault B; de Chaisemartin C; Esterni B; Lelong B; Viret F; Giovannini M; Monges G; Delpero JR; Bories E; Turrini O; Viens P; Salem N Int J Radiat Oncol Biol Phys; 2011 Jun; 80(2):483-91. PubMed ID: 21093174 [TBL] [Abstract][Full Text] [Related]
66. Induction chemotherapy with capecitabine and oxaliplatin followed by chemoradiotherapy before total mesorectal excision in patients with locally advanced rectal cancer. Schou JV; Larsen FO; Rasch L; Linnemann D; Langhoff J; Høgdall E; Nielsen DL; Vistisen K; Fromm A; Jensen BV Ann Oncol; 2012 Oct; 23(10):2627-2633. PubMed ID: 22473488 [TBL] [Abstract][Full Text] [Related]
67. Evaluation of short-course radiotherapy followed by neoadjuvant bevacizumab, capecitabine, and oxaliplatin and subsequent radical surgical treatment in primary stage IV rectal cancer. van Dijk TH; Tamas K; Beukema JC; Beets GL; Gelderblom AJ; de Jong KP; Nagtegaal ID; Rutten HJ; van de Velde CJ; Wiggers T; Hospers GA; Havenga K Ann Oncol; 2013 Jul; 24(7):1762-1769. PubMed ID: 23524865 [TBL] [Abstract][Full Text] [Related]
68. A phase II study of neoadjuvant bevacizumab plus capecitabine and concomitant radiotherapy in patients with locally advanced rectal cancer. Gasparini G; Torino F; Ueno T; Cascinu S; Troiani T; Ballestrero A; Berardi R; Shishido J; Yoshizawa A; Mori Y; Nagayama S; Morosini P; Toi M Angiogenesis; 2012 Mar; 15(1):141-50. PubMed ID: 22212406 [TBL] [Abstract][Full Text] [Related]
69. Phase II study of preoperative irradiation and chemotherapy with capecitabine in patients with locally advanced rectal carcinoma. Lay GC; Caraul B; Dessì M; Orrù S; Murtas R; Deidda MA; Farigu R; Farci D; Maxia L; Casula G; Amichetti M J Exp Clin Cancer Res; 2007 Mar; 26(1):61-70. PubMed ID: 17550133 [TBL] [Abstract][Full Text] [Related]
70. Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. Cassidy J; Clarke S; Díaz-Rubio E; Scheithauer W; Figer A; Wong R; Koski S; Lichinitser M; Yang TS; Rivera F; Couture F; Sirzén F; Saltz L J Clin Oncol; 2008 Apr; 26(12):2006-12. PubMed ID: 18421053 [TBL] [Abstract][Full Text] [Related]
71. A phase I dose escalation study of continuous oral capecitabine in combination with oxaliplatin and pelvic radiation (XELOX-RT) in patients with locally advanced rectal cancer. Glynne-Jones R; Sebag-Montefiore D; Maughan TS; Falk SJ; McDonald AC Ann Oncol; 2006 Jan; 17(1):50-6. PubMed ID: 16284060 [TBL] [Abstract][Full Text] [Related]
72. Preoperative radiotherapy of advanced rectal cancer with capecitabine and oxaliplatin with or without cetuximab: A pooled analysis of three prospective phase I-II trials. Weiss C; Arnold D; Dellas K; Liersch T; Hipp M; Fietkau R; Sauer R; Hinke A; Rödel C Int J Radiat Oncol Biol Phys; 2010 Oct; 78(2):472-8. PubMed ID: 20133081 [TBL] [Abstract][Full Text] [Related]
73. Comparison of 5-fluorouracil/leucovorin and capecitabine in preoperative chemoradiotherapy for locally advanced rectal cancer. Kim DY; Jung KH; Kim TH; Kim DW; Chang HJ; Jeong JY; Kim YH; Son SH; Yun T; Hong CW; Sohn DK; Lim SB; Choi HS; Jeong SY; Park JG Int J Radiat Oncol Biol Phys; 2007 Feb; 67(2):378-84. PubMed ID: 17097835 [TBL] [Abstract][Full Text] [Related]
74. [Analysis on efficacy and safety of total neoadjuvant therapy in patients with locally advanced rectal cancer with high risk factors]. Ouyang GL; Meng WJ; Shu P; Deng XB; Wu B; Jiang D; Zhuang H; Shen YL; Zhou ZG; Wang ZQ; Wang X Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Apr; 22(4):349-356. PubMed ID: 31054549 [No Abstract] [Full Text] [Related]
75. Prospective phase II trial of neoadjuvant chemo-radiotherapy with Oxaliplatin and Capecitabine in locally advanced rectal cancer (XELOXART). Ricardi U; Racca P; Franco P; Munoz F; Fanchini L; Rondi N; Dongiovanni V; Gabriele P; Cassoni P; Ciuffreda L; Morino M; Filippi AR; Aglietta M; Bertetto O Med Oncol; 2013; 30(2):581. PubMed ID: 23606239 [TBL] [Abstract][Full Text] [Related]
76. Adjuvant treatment for locally advanced rectal cancer patients after preoperative chemoradiotherapy: when, and for whom? De Stefano A; Moretto R; Bucci L; Pepe S; Romano FJ; Cella AC; Attademo L; Rosanova M; De Falco S; Fiore G; Raimondo L; De Placido S; Carlomagno C Clin Colorectal Cancer; 2014 Sep; 13(3):185-91. PubMed ID: 25080847 [TBL] [Abstract][Full Text] [Related]
77. Postoperative XELOX therapy for patients with curatively resected high-risk stage II and stage III rectal cancer without preoperative chemoradiation: a prospective, multicenter, open-label, single-arm phase II study. Mizushima T; Ikeda M; Kato T; Ikeda A; Nishimura J; Hata T; Matsuda C; Satoh T; Mori M; Doki Y BMC Cancer; 2019 Sep; 19(1):929. PubMed ID: 31533662 [TBL] [Abstract][Full Text] [Related]
78. Preoperative treatment with capecitabine, cetuximab and radiotherapy for primary locally advanced rectal cancer--a phase II clinical trial. Eisterer W; De Vries A; Öfner D; Rabl H; Koplmüller R; Greil R; Tschmelitsch J; Schmid R; Kapp K; Lukas P; Sedlmayer F; Höfler G; Gnant M; Thaler J; Anticancer Res; 2014 Nov; 34(11):6767-73. PubMed ID: 25368289 [TBL] [Abstract][Full Text] [Related]
79. [A case of advanced rectal cancer that showed complete response to the addition of XELOX+bevacizumab therapy to preoperative chemoradiotherapy with S-1/CPT-11]. Takahashi T; Namiki K; Matsumoto H; Konno F; Mitsui K; Yoshida R Gan To Kagaku Ryoho; 2014 May; 41(5):653-5. PubMed ID: 24917016 [TBL] [Abstract][Full Text] [Related]
80. Neoadjuvant chemoradiation for rectal cancer: is more better? Patel A; Puthillath A; Yang G; Fakih MG Oncology (Williston Park); 2008 Jun; 22(7):814-26; discussion 826, 828-31, 836. PubMed ID: 18619122 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]